Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study
Abbas Iqbal, Abubakar Afzal, Zaib Un Nisa. Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study. // International Journal of Rheumatic Diseases. – 2026. – DOI: 10.1111/1756-185x.70964. – URL: https://onlinelibrary.wiley.com/doi/10.1111/1756-185x.70964?af=R
Abbas Iqbal, Abubakar Afzal, & Zaib Un Nisa (2026). Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70964
Abbas Iqbal, et al. “Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study.” International Journal of Rheumatic Diseases, 2026. doi:10.1111/1756-185x.70964.
@article{Iqbal2026,
title = {Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study},
author = {Iqbal, Abbas and Afzal, Abubakar and Nisa, Zaib Un},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
doi = {10.1111/1756-185x.70964},
url = {https://onlinelibrary.wiley.com/doi/10.1111/1756-185x.70964?af=R}
}
Objective Black patients with systemic sclerosis (scleroderma) have more severe disease than White patients. We investigated whether racial differences in therapeutic responses to mycophenolate mofetil (MMF) could explain this...